French patient-reported experience of diagnosis, management and burden of neuroendocrine tumors-Reference-Cited by-同舟云学术

French patient-reported experience of diagnosis, management and burden of neuroendocrine tumors

Published:2020-06-01 Issue:2 Volume:7 Page:
ISSN:2045-0869
Container-title:International Journal of Endocrine Oncology
language:en
Short-container-title:International Journal of Endocrine Oncology

Author:

Lombard-Bohas Catherine¹^ORCID,Cao Christine Do²^ORCID,Metges Jean-Philippe³,Philippe Ruszniewski ⁴,Smith Denis⁵^ORCID,Guimbaud Rosine⁶^ORCID,Lepage Côme⁷,Ron Hollander ⁸,Goldstein Grace⁹^ORCID,Wolin Edward¹⁰,Santos Alexandre¹¹^ORCID,Baudin Eric¹²

Affiliation:

1. Hopital Edouard Herriot, Service Gastro-Enterologie, Lyon, France

2. Centre Hospitalier Universitaire de Lille, Service Endocrinologie, Lille, France

3. Centre Hospitalier Régional Universitaire de Brest, Pôle Régional de Cancérologie, Brest, France

4. Université de Paris et Service de Pancréatologie, Hôpital Beaujon, Clichy, France

5. Centre Hospitalier Universitaire de Bordeaux, Service d'Oncologie Médicale, Bordeaux, France

6. Centre Hospitalier Universitaire de Toulouse, Service d'Oncologie Médicale, Toulouse, France

7. Université de Bourgogne, Dijon, France

8. International Neuroendocrine Cancer Alliance (INCA), Newton, MA, USA

9. The Carcinoid Cancer Foundation, Inc., Mount Kisco, NY, USA

10. Center for Carcinoid and Neuroendocrine Tumors, Icahn School of Medicine at Mount Sinai, New York, NY, USA

11. Novartis Oncologie, Rueil-Malmaison, France

12. Institute Gustave Roussy, Service de Médecine Nucléaire, Villejuif, France

Abstract

Background: There is a lack of knowledge regarding the experience of patients with neuroendocrine tumors (NET) in France. Materials & methods: A patient survey that captured information on diagnosis, disease impact/management and awareness was conducted. Data of respondents from France were analyzed and compared with US data as a reference. Results: Key topics included delays in diagnosis, negative impact on quality of life, patient access to NET medical experts and treatments, and information on NET and treatments. Significant differences were observed between France and the USA regarding NET diagnosis. Conclusion: This survey highlights the considerable burden experienced by patients in France with NET and differences in patient experience between France and the USA that may result from different healthcare and social systems.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism

Link

https://www.futuremedicine.com/doi/pdf/10.2217/ije-2020-0013

Reference23 articles.

1. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

2. Clinical Presentation and Diagnosis of Neuroendocrine Tumors

3. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

4. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors

5. Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare cost by primary tumour, functioning status and treatment among patients with metastatic neuroendocrine tumours: The LyREMeNET study;Journal of Neuroendocrinology;2022-01-25